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Introduction
Anemia is one of the commonest extra - intestinal complications of IBD. It is more common in 
children than adults [1]; affecting an estimated 70% of children with IBD [2]. It occurs more frequently 
in CD than UC [3]. Anemia in IBD is multifactorial and closely associated with IBD activity. The 
leading cause is IDA followed by anemia of chronic disease. ID results from gastrointestinal blood 
loss, poor dietary intake and reduced iron bioavailability. Iron malabsorption is a contributing 
factor especially in CD affecting the small bowel [4]. Nearly 90% of children with IBD have ID with 
or without associated anemia [1]. It is increasingly recognized that IDA is a significant contributor 
to morbidity in IBD. Chronic IDA in children causes fatigue, impairs cognitive development and is 
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Abstract
Objectives: Iron deficiency anemia (IDA) frequently complicates inflammatory bowel disease 
(IBD) in children and adults. Oral iron may exacerbate gastrointestinal symptoms and absorption 
may be insufficient in intestinal inflammation. Even where oral iron is successful, repletion of iron 
stores can be unacceptably slow. Intravenous (IV) iron compounds were in the past associated with 
serious adverse reactions and historically were considered a last resort in children. New generation 
preparations have a safer profile in adults although reluctance to use them in children may persist, 
where safety data is lacking. We investigate the safety and efficacy of ferric carboxymaltose (FCM) 
and iron sucrose (IS) in children.
Methods: We retrospectively identified all children with IBD who received parenteral iron over 
a 38 month period in a single regional referral centre. Safety, tolerability and adverse events were 
established by case note review. Efficacy was assessed by change in hematinic indices pre- and post-
treatment.
Results: 47 children (18 male; median age 14yrs, range 3-17) received a total of 104 iron infusions. 
44% (21) had Crohn’s disease (CD); 56% (27) ulcerative colitis (UC). 40 received FC, eight IS 
and one both. Three children developed mild rash post infusion which resolved quickly with 
chlorphenamine. Mean increase in hemoglobin (Hb) was 2.5g/dl (0.3-5.8). Iron levels increased by 
a mean of 8.4 g/dl (1-25), transfer in saturation by 16.2% (2-47). Transfer in decreased by 0.84 g/dl 
(0.3-3.4).
Conclusion: New generation parenteral iron preparations are safe, well tolerated and efficacious in 
children with IDA and IBD.
What is known: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel 
disease (IBD) and a significant contributor to morbidity.
IDA should be actively treated in IBD.
Parenteral iron is effective and relatively safe in adults.
What is new: The intravenous iron preparations ferric carboxymaltose (FCM) and iron sucrose 
(IS) are effective treatments for IDA in children with IBD. The safety profiles of FCM and IS are 
favourable, and similar in children to that in adults.
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Patient Age/Sex Disease Hb (g/dL) Iron (µmol/L) Dose (mg) No of infusions/preparation
1 16F CD 8.8 3 1500 2 FCM
2 14M UC 8.2 2 1000 1 FCM
3 15F CD 8.4 4 900 1 FCM
4 17M CD 9.4 3 2000 2 FCM
5 16F CD 9.2 8 1500 2 FCM
6 13F UC 8.8 2 500 1 FCM
7 15M UC 8.3 4 1500 2 FCM
8 17M CD 11.0 8 1000 1 FCM
9 13M CD 9.2 3 1500 2 FCM
10 14F UC 10.3 7 1000 1 FCM
11 13M UC 9.0 3 800 1 FCM
12 13F CD 7.7 2 800 1 FCM
13 15F UC 9.1 5 1500 2 FCM
14 13F CD 11.1 4 1000 1 FCM
15 12M UC 9.3 3 1500 2 FCM
16 13F CD 9.6 2 1500 2 FCM
17 16F CD 8.6 9 1500 2 FCM
18 13F UC 8.8 6 1500 2 FCM
19 15F CD 8.9 3          500 1 FCM
20 12F UC 9.3 3 1500 2 FCM
21 16M CD 12.1 4 1000 1 FCM
22 12M UC 9.7 3 1500 2 FCM
23 16F UC 9.5 3 1000 1 FCM
24 16M CD 8.9 4 1500 2 FCM
25 15F UC 8.2 3 1500 2 FCM
26 16F CD 10.3 3 1000 1 FCM
27 14F CD 7.5 3 800 1 FCM
28 16F UC 10.3 4 1000 1 FCM
29 12F UC 9.8 2 500 1 FCM
30 15M CD 9.7 2 1500 2 FCM
31 16F UC 11.6 2 1000 1 FCM
32 14F CD 10 2 1000 1 FCM
33 16M CD 9.6 3 3000 2 FCM
34 13M UC 10 3 850 1 FCM 
35 15F UC 8.6 3 1500 2 FCM
36 16F CD 10.3 3 930 1 FCM
37 14M CD 10.4 6 500 1 FCM
38 14F UC 8.3 unavailable 1500 2 FCM
39 16M UC 8.8 2 1000 1 FCM
40 13F UC 8.5 2 1000 1 FCM
41 12M UC 8.5 2 320 4 IS
42 8M UC 8.4 3 420 6 IS
16 12F CD 7.3 2 600 6 IS
43 10F UC 9.1 3 630 7 IS
44 10F UC 8.6 2 640 8 IS
45 3M UC 8.8 1 390 8 IS
46 5F UC 8.3 2 45 1 IS
47 9M UC 10.2 5 528 6 IS
Table 1: Patient demographics, initial haematinics and iron therapy.
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associated with lower intelligence quotients (IQ), attention deficit and 
other behavioral disorders [5]. Immune regulation and growth are 
also negatively impacted [6]. These effects are apparent in ID even in 
the absence of anemia. Adult IBD patients who are anemic report low 
quality of life (QOL) indices and there is a marked improvement in 
QOL when HB is corrected in adults with IBD [7]. For these reasons 
early recognition and prompt and effective treatment of ID (A) are of 
paramount importance in IBD care. Oral iron supplementation may 
be considered first line therapy, although issues with tolerance and 
adherence to prolonged treatment courses often impair therapeutic 
success. Blood transfusion as a therapy for IDA carries costs and risks 
which are well recognized. Newer intravenous (IV) iron preparations 
with a more favorable side effect profile have become available in the 
last decade including iron sucrose (IS) and ferric carboxymaltose 
(FCM) which have been shown to be safe and effective in adults 
[8-10]. Only a small number of studies on the safety and efficacy of 
modern IV iron products have been conducted in children. Most of 
these studied IS not FCM and concerned small numbers of children 
with chronic kidney disease [11-14]. More recently investigators have 
shown encouraging safety and efficacy of IS in 24 children with IBD 
and IDA [15].
Here we describe our 38-month experience of FCM and IS in 
children with IBD with a focus on safety and efficacy.
Methods
All children with IBD who received IV iron in a single regional 
referral centre between April 2013 and May 2016 were retrospectively 
identified via pharmacy records. Inclusion criteria were therefore 
IBD and IDA. In most cases oral iron was used as first line treatment 
for IDA. IV iron was used in the following circumstances: (a) patient 
reported side effects with oral iron; (b) non-resolution of IDA with 
3 months of oral iron; (c) physician assessment of severity of either 
IBD or IDA contraindicates trial of oral iron. Anemia was defined 
as HB below reference range for age and gender according to the 
World Health Organization (WHO) [16]. ID was diagnosed by 
the combination of low serum iron, low mean red cellular volume 
(MCV), high transfer in and low iron saturation. Ferritin falls in ID, 
but rises in the acute phase [17], complicating its interpretation as a 
marker for IDA in IBD. Ferritin was therefore defined as low in the 
context of CRP (ferritin <30 if CRP <10 and ferritin <100 if CRP >10). 
Children with severe atopy or allergies or history of prior anaphylaxis 
were excluded from the study, and were not offered IV iron therapy. 
Choice of iron preparation was based primarily on patient age, with 
those under 12 years of age receiving IS and those over 12 years 
FCM. Demographic data, disease status, iron preparation type, dose 
and number of infusions were recorded. Dosage was calculated as a 
function of body weight and HB, as per manufacturers’ recommended 
dosing schedules. Iron preparations were infused according to British 
National Formulary guidelines. FCM infusions were administered 
over 15 to 30 minutes; IS over 50 to 70 minutes. All patients completed 
a two hour inpatient observation period post infusion during which 
vital signs were recorded at regular intervals.
Adverse reactions were identified by detailed review of written 
case notes, nursing observations and nursing, pharmacy and medical 
electronic records. Efficacy was assessed by pre- treatment and post-
treatment iron, transfer in saturation, ferritin, transfer in and HB 
levels. Change in CRP and ESR were also recorded.
Results
47 children with IBD received 104 IV iron infusions over the 
study period (Table 1). 29 children were female and 18 male. Mean 
age was 13.5 years, ranging from 3 to 17 years. 20 had CD (44%) 
and 27 UC (56%). 40 patients received 58 FCM infusions, average 
1.5 infusions per patient. Eight patients received 46 IS infusions; 
average 5.8 infusions per patient. One patient initially completed 
a course of IS infusions and 11 months later received FCM as she 
moved age group (thus total number of infusion episodes studied = 
48). The doses ranged from (500 to 1000) mg per infusion for FCM 
and 70 to 100 mg per infusion for IS. All children over 12 years of age 
received FCM. Patients under 12 years received IS, which, although 
also off licence, is in line with greater past pediatric experience and 
wide spread pediatric practice in the United Kingdom. Choice of iron 
preparation for children between their 12th and 13th birthdays was 
made on a case by case basis. Three 12 year olds received FCM and 
two received IS. Safety. 2/40 patients who received FCM developed 
rash after completing their first infusion, giving a reaction rate of 5%. 
Both reactions were mild. In patient 3 rash appeared 30 minutes post 
infusion, with a small drop in systolic blood pressure which resolved 
rapidly. The rash resolved after a single dose of IV chlorphenamine 
with no further complications. Subsequent doses of FCM were not 
given and the patient continued on oral iron therapy. Patient 10 
developed rash one hour post infusion with no systemic compromise. 
She received a single dose of IV chlorphenamine after which the 
rash resolved. She did not require a second dose of FCM as adequate 
increment in HB was achieved with single dose. One patient (case 
46) of the eight who received IS developed facial itching and mild eye 
puffiness 15 minutes into her first infusion, giving a reaction rate of 
12.5%. There was no systemic compromise and symptoms resolved 
with single dose IV chlorphenamine.
Efficacy of the 40 patients who received FCM, 18 received a 
second dose 1-4 weeks later. Of the 22 children who received single 
dose, three did not attend for their scheduled second infusion, in one 
n= Mean SD Min Max
Index 48 13.52 2.88 3 17
Hb
Pre 48 9.26 1.01 7.3 12.1
Post 44 11.8 1.28 9.3 15
Tfer saturation
Pre 44 4.66 2.91 1 15
Post 40 20.95 11.02 3 47
CRP
Pre 20 8.87 15.47 .2 65.0
Post 19 8.66 12.10 .2 46.0
ESR
Pre 16 37.50 23.67 5.0 112.0
Post 18 22.06 17.80 2.0 73.0
Transferrin
Pre 42 3.06 0.50 2.3 4.0
Post 35 2.24 0.42 1.7 4.0
Ferritin
Pre 30 11.3 11.88 2 56
Post 23 146.43 133.08 10 446
Iron
Pre 47 3.38 1.78 1 9
Post 40 11.78 5.21 3 25
Table 2: Haematinic indices pre- and post-treatment. Data were imported 
into STATA version 14.  Descriptive statistics: mean, standard deviation (SD), 
minimum and maximum were calculated for pre- and post-treatment values of Hb, 
Tfer saturation, CRP, ESR, transferrin, ferritin and iron. Paired sample Student’s 
T Tests for paired differences were calculated for pre- and post-treatment values 
for each variable. Hb, transferrin, transferrin saturation, Fe and ESR: p=<0.0001. 
Ferritin: p=<0.0002.  CRP: p=0.94.
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case the second dose was cancelled because of adverse reaction; one 
was less than 35 kg –as per administration guidelines and 17 achieved 
adequate increment in HB with single dose. HB was recorded pre-
infusion in all 48 infusion episodes and post-infusion in 44/48 cases. 
Mean HB pre-infusion was 9.3 (range 7.3 to 12.1) g/dl. Mean HB 
post treatment was 11.8, an increase of 2.5 per patient (p=<0.0001). 
There was significant improvement in all hematinic indices following 
infusion (Table 2 ) (Figure 1,2).
Discussion
Published evidence strongly supports both proactive treatment 
of IDA in IBD, and the use of newer IV iron preparations which 
are efficacious with fewer doses and less allergenic than their 
predecessors. As in many other areas of pediatric practice, treatment 
of children has relied upon the extrapolation of adult research. 
Here we contribute safety and efficacy data for IV iron therapy in 
pediatric IBD. Oral ferrous supplements are oxidized in the gut, 
produce activated hydroxyl radicals that affect the mucosa [18] and 
may provoke gastrointestinal symptoms including bloating, nausea 
and pain which can be exacerbated in patients with IBD [19]. In 
inflammatory diseases, iron absorption is reduced and increased 
hepcidin, an acute phase protein, plays a key role. In health, 
hepcidin levels rise with total body iron stores and protect against 
iron overload. Hepcidin is up-regulated in systemic inflammatory 
states by interleukin (IL) 6 and IL-1, and impairs absorption of oral 
iron via multiple mechanisms [20]. Adherence to oral iron therapy, 
particularly in adolescent IBD patients, is frequently suboptimal [21]. 
Even in the adherent patient, several months of oral supplementation 
may be required to achieve target HB. The first IV iron introduced in 
the 1930s, an iron oxyhydroxide complex [22], had major side effects 
and was only indicated in rare circumstances [23]. In the 1950s a high 
molecular weight iron dextran (HMW-ID) was developed in which 
the iron oxyhydroxide complex was surrounded by a shell of dextran 
polymers [24]. This improved its bioavailability and side effect 
Figure 1:  A) Hbpre- and post-treatment (g/dL) (normal ranges(NR) differ with age and sex). p=<0.0001. B)  Iron pre- and post-treatment (NR 7-27 µg/dL). 
p=<0.0001. C) Ferritin pre- and post-treatment (NR 7-140 µg/dL).  p=<0.0002. D) Transferrin saturation pre- and post-treatment (NR 16-55%).  p=<0.0001. E) 
Transferrin pre- and post-treatment (NR 1.7-3.4 g/L).  p=<0.0001.
Figure 2: A) ESR (mm/hr) p=<0.0001.  B) CRP (mg/ml) p=0.94 pre- and 
post-treatment.
profile, however allergic reactions were frequent [25]. Gradually, low 
molecular weight iron dextran compounds became available which 
caused fewer adverse reactions [26]. Later ferric gluconate (FG) 
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was introduced and was safer than iron dextran [27]. In 2000 iron 
sucrose (IS) came into clinical use, whose incidence of anaphylaxis 
was lower at 0.002%; compared to 0.04% with FG and 0.6-2.3% 
with HMW-ID [28]. The biggest drawback of IS its low maximum 
single administrable dose, resulting in multiple separate infusions to 
reach therapeutic dose. Finally in 2007 ferric carboxymaltose (FCM) 
became available with a license in Europe for patients above 14 yrs. 
A single dose of 1000 mg of iron can be given, and administered 
relatively fast, over 15-60 minutes [29], with no requirement for test 
dose, thus reducing hospital attendance times and costs. Of the 47 
children in our series who received IV iron none experienced major 
or lasting adverse event. In our series FCM was associated with a 
5% mild reaction rate (rash) and IS with a 12.5% mild reaction rate 
(itch and eye swelling). These numbers do not allow comparative 
conclusions to be drawn between the two iron preparations in terms 
of safety, however we provide evidence that parenteral iron and in 
particular FCM is safe and well tolerated in children. We show that 
IV iron is a highly efficacious treatment for IDA in children with IBD, 
inducing clinically and statistically significant increments in HB, Fe 
and transfer in saturation and reductions in transfer in and ESR. The 
reduction in ESR was not paralleled by significant reduction in CRP 
and reflects resolution of IDA rather than change in IBD activity. As 
well as its lower reported incidence of anaphylaxis, FCM offers a less 
onerous dosing schedule, no requirement for test dose and shorter 
infusion time in contrast to IS. In our series we demonstrate safety of 
FCM in children at least as young as 12 years. This is an off-label use 
of this medication (<14 years of age). Other investigators have more 
recently demonstrated safety of FCM in even younger age groups, not 
specific to IBD [30]. We have selected lower risk cases by excluding 
those with a personal history of severe allergy, atopy or anaphylaxis 
to other agents. Whilst the safety profile of parenteral iron in children 
is probably comparable to that in adults, oral iron remains a safer and 
less costly option, and should be trialed in the first instance in most 
cases, where IDA is mild to moderate, IBD activity is quiescent and 
there is no history of intolerance.
We acknowledge the limitations of this study associated with 
its retrospective design and heterogeneous clinical nature. Whilst 
prospective randomized trial design is needed in the field, the current 
study provides supporting evidence for the safety and efficacy of new 
generation IV iron preparations in the treatment of IBD-associated 
IDA in children.
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